OBJECTIVE: Whereas epidemiological studies show that levels of low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C) predict incident cardiovascular disease (CVD), there is limited evidence relating lipoprotein subfractions and composite measures of subfractions to risk for CVD in prospective cohort studies. METHODS AND RESULTS: We tested whether combinations of lipoprotein subfractions independently predict CVD in a prospective cohort of 4594 initially healthy men and women (the Malmö Diet and Cancer Study, mean follow-up 12.2 years, 377 incident cardiovascular events). Plasma lipoproteins and lipoprotein subfractions were measured at baseline with a novel high-resolution ion mobility technique. Principal component analysis (PCA) of subfraction concentrations identified 3 major independent (ie, zero correlation) components of CVD risk, one representing LDL-associated risk, a second representing HDL-associated protection, and the third representing a pattern of decreased large HDL, increased small/medium LDL, and increased triglycerides. The last corresponds to the previously described "atherogenic lipoprotein phenotype." Several genes that may underlie this phenotype-CETP, LIPC, GALNT2, MLXIPL, APOA1/A5, LPL-are suggested by SNPs associated with the combination of small/medium LDL and large HDL. CONCLUSIONS: PCA on lipoprotein subfractions yielded three independent components of CVD risk. Genetic analyses suggest these components represent independent mechanistic pathways for development of CVD.
OBJECTIVE: Whereas epidemiological studies show that levels of low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C) predict incident cardiovascular disease (CVD), there is limited evidence relating lipoprotein subfractions and composite measures of subfractions to risk for CVD in prospective cohort studies. METHODS AND RESULTS: We tested whether combinations of lipoprotein subfractions independently predict CVD in a prospective cohort of 4594 initially healthy men and women (the Malmö Diet and Cancer Study, mean follow-up 12.2 years, 377 incident cardiovascular events). Plasma lipoproteins and lipoprotein subfractions were measured at baseline with a novel high-resolution ion mobility technique. Principal component analysis (PCA) of subfraction concentrations identified 3 major independent (ie, zero correlation) components of CVD risk, one representing LDL-associated risk, a second representing HDL-associated protection, and the third representing a pattern of decreased large HDL, increased small/medium LDL, and increased triglycerides. The last corresponds to the previously described "atherogenic lipoprotein phenotype." Several genes that may underlie this phenotype-CETP, LIPC, GALNT2, MLXIPL, APOA1/A5, LPL-are suggested by SNPs associated with the combination of small/medium LDL and large HDL. CONCLUSIONS: PCA on lipoprotein subfractions yielded three independent components of CVD risk. Genetic analyses suggest these components represent independent mechanistic pathways for development of CVD.
Authors: J M Ordovas; L A Cupples; D Corella; J D Otvos; D Osgood; A Martinez; C Lahoz; O Coltell; P W Wilson; E J Schaefer Journal: Arterioscler Thromb Vasc Biol Date: 2000-05 Impact factor: 8.311
Authors: Melissa A Austin; Philippa J Talmud; Federico M Farin; Deborah A Nickerson; Karen L Edwards; Donna Leonetti; Marguerite J McNeely; Hannah-Malia Viernes; Steve E Humphries; Wilfred Y Fujimoto Journal: Biochim Biophys Acta Date: 2004-01-20
Authors: S E Humphries; L Berglund; C R Isasi; J D Otvos; D Kaluski; R J Deckelbaum; S Shea; P J Talmud Journal: Nutr Metab Cardiovasc Dis Date: 2002-08 Impact factor: 4.222
Authors: Lewis Kuller; Alice Arnold; Russell Tracy; James Otvos; Greg Burke; Bruce Psaty; David Siscovick; David S Freedman; Richard Kronmal Journal: Arterioscler Thromb Vasc Biol Date: 2002-07-01 Impact factor: 8.311
Authors: Ronald M Krauss; Kathleen Wojnooski; Joseph Orr; J Casey Geaney; Cathy Anne Pinto; Yang Liu; John A Wagner; Julie Mabalot Luk; Amy O Johnson-Levonas; Matt S Anderson; Hayes M Dansky Journal: J Lipid Res Date: 2011-12-17 Impact factor: 5.922
Authors: Masumi Ai; Seiko Otokozawa; Bela F Asztalos; Yasuki Ito; Katsuyuki Nakajima; Charles C White; L Adrienne Cupples; Peter W Wilson; Ernst J Schaefer Journal: Clin Chem Date: 2010-04-29 Impact factor: 8.327
Authors: Kiran Musunuru; Alanna Strong; Maria Frank-Kamenetsky; Noemi E Lee; Tim Ahfeldt; Katherine V Sachs; Xiaoyu Li; Hui Li; Nicolas Kuperwasser; Vera M Ruda; James P Pirruccello; Brian Muchmore; Ludmila Prokunina-Olsson; Jennifer L Hall; Eric E Schadt; Carlos R Morales; Sissel Lund-Katz; Michael C Phillips; Jamie Wong; William Cantley; Timothy Racie; Kenechi G Ejebe; Marju Orho-Melander; Olle Melander; Victor Koteliansky; Kevin Fitzgerald; Ronald M Krauss; Chad A Cowan; Sekar Kathiresan; Daniel J Rader Journal: Nature Date: 2010-08-05 Impact factor: 49.962
Authors: Michael Y Tsai; Brian T Steffen; Weihua Guan; Robyn L McClelland; Russell Warnick; Joseph McConnell; Daniel M Hoefner; Alan T Remaley Journal: Arterioscler Thromb Vasc Biol Date: 2013-11-14 Impact factor: 8.311
Authors: Lars Berglund; John D Brunzell; Anne C Goldberg; Ira J Goldberg; Frank Sacks; Mohammad Hassan Murad; Anton F H Stalenhoef Journal: J Clin Endocrinol Metab Date: 2012-09 Impact factor: 5.958